Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Invitation to Immunovia’s Q1 presentation

May 17, 2023

LUND (SWEDEN) – Immunovia will publish its first quarter 2023 results on May 23, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com

 

Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.

 

Telephone numbers and webcast

Call any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts.

 

Sweden: +46 (0)8 5051 0031
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13

 

Link to the webcast: https://access.creomediamanager.com/registration/058aa458-36d2-4352-9dbf-1894dc75828d?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F058aa458-36d2-4352-9dbf-1894dc75828d

To ask questions, it is necessary to dial in. A recording of the presentation will be available on Immunovia’s website.

 

For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08

 

 

About Immunovia
Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. 

 

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. 

 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.  

 

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated, addressable market size of 1.8 million individuals per year who could benefit from our test. 

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com 

 

                                                                           ###

Press release (PDF)